Catalyst
Slingshot members are tracking this event:
Boehringer Ingelheim's Praxbind Approved by FDA for Use As an Emergency Reversing Agent in Patients Taking Pradaxa
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PTLA |
|
|
BXLT |
|
|
PFE |
|
|
BMY |
|
|
Boehringer Ingelheim |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 16, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Emergency Reversing Agent, Anticoagulant, Pradaxa, Stroke, Systemic Blood Clots, Atrial Fibrillation, Deep Venous Thrombosis, Pulmonary Embolism, Dabigatran, Praxbind
